Marc Vandemeulebroecke

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

Wolfgang Hueber, Bruce E. Sands, Steve Lewitzky et al. · Gut · 2012 · 1.5K citations · Full text

Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials

Alexa B. Kimball, Gregor B. E. Jemec, Afsáneh Alavi et al. · The Lancet · 2023 · 270 citations

Inflammation, Double-blind Phase 3, Week 16 +5

Comments on the Draft Guidance on “Adaptive Design Clinical Trials for Drugs and Biologics” of the U.S. Food and Drug Administration

Werner Brannath, Hans Ulrich Burger, Ekkehard Glimm et al. · Journal of Biopharmaceutical Statistics · 2010 · 193 citations

U.s. Food, Health Policy, Clinical Trial Management +15

AFQ056 treatment of levodopa‐induced dyskinesias: Results of 2 randomized controlled trials

Daniela Berg, Jana Godau, Claudia Trenkwalder et al. · Movement Disorders · 2011 · 172 citations

The stratified win ratio

Gaohong Dong, Junshan Qiu, Duolao Wang et al. · Journal of Biopharmaceutical Statistics · 2017 · 82 citations

Clinical Endpoint, Game Theory, Composite Endpoint +21